Skip to content
Menu

Braveheart Bio, Inc. BRVE

Full chart Compare
Set alert

Price alert · BRVE

All alert types
19.27 USD +0.74 (+3.99%)

Regular-session close

19.27 0.00 0.00%

After hours · Nov 19, 4:00 PM ET

18.24 Day range 19.50
17.42 52-week range 30.00
YTD
-35.34%
1 year
-35.34%

5D -1.56 (-7.64%)

181920FriMonTueWedThu18.85
Market cap
1.58B
EPS (ttm)
-6.85
Shares out
82.07M
Forward P/E
-9.68
YTD return
-35.34%
1-year return
-35.34%
50-day average
21.51
200-day average
23.43
Enterprise value
1.32B
Volume
1.11M
Avg volume
465.21K
Open
18.68
Previous close
18.53
Day's range
18.24 – 19.50
52-week range
17.42 – 30.00
Analysts
Strong Buy
Price target
45.50 (+136.1%)
Earnings date
Feb 9, 2027

Key statistics

Price / book
3.18
Total cash
349.27M
Total debt
515.00K

Fundamental scorecard

3 of 25 checks passed on BRVE’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth No data
  • Profitability No data
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
BRVE Revenue — quarterly 0
BRVE Net income — quarterly -26.50M
BRVE EPS — quarterly -0.51

Earnings

BRVE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 9, 2027Sep 30, 2026-0.438———
Nov 10, 2026Jun 30, 2026-0.438-0.51-0.07-16.44%

Upgrades / downgrades

BRVE analyst upgrades and downgrades
DateFirmActionFromTo
Oct 20, 2026Cantor FitzgeraldreitOverweightOverweight

About Braveheart Bio, Inc.

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on BRVE — it syncs with the Stock Master app.

Insider holders

BRVE insider holders
InsiderRelationLatest transactionDateShares held
CHIMOVITS EREZDirector and Beneficial Owner of more than 10% of a Class of SecurityPurchaseAug 6, 20260
JIANGSU HENGRUI PHARMACEUTICALS CO. LTD.Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityAug 6, 20267,420,090
LUBNER DAVID CHARLESDirectorPurchaseAug 6, 202655,555
MURDOCH TRAVISChief Executive OfficerPurchaseAug 6, 20268,333,640
RICKEY JAMES PAULChief Financial OfficerPurchaseAug 6, 2026703,575
VIEHBACHER CHRISTOPHERDirectorPurchaseAug 6, 2026759,857

Institution ownership

BRVE institution ownership
Holder% heldSharesValueReported
FCPM III Services B.V.24.29%21,826,024420.59MSep 29, 2026
Orbimed Advisors LLC.13.55%12,175,159234.62MSep 29, 2026
a16z Capital Management, L.L.C.11.39%10,232,420197.18MSep 29, 2026
FMR, LLC8.44%7,585,769146.18MSep 29, 2026
Frazier Life Sciences Management, L.P. 5.86%5,267,321101.50MSep 29, 2026
Enavate Sciences Gp, LLC 4.09%3,674,65670.81MSep 29, 2026

Fund ownership

BRVE fund ownership
Holder% heldSharesValueReported
SmallCap World Fund Inc2.53%2,273,15143.80MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio1.15%1,035,86219.96MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund0.87%779,60015.02MSep 29, 2026
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 0.80%718,20013.84MSep 29, 2026
Fidelity Select Portfolios-Select Biotechnology Portfolio0.62%559,56410.78MSep 29, 2026
Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund0.56%500,0009.63MSep 29, 2026